Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline

M J Casarejos1, J Menéndez, R M Solano

  • 1Department of Neurobiology, Hospital Ramon y Cajal, Madrid, Spain.

Insights

Parkinson

Area of Science:

  • Neuroscience
  • Genetics
  • Toxicology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder with unknown causes in most cases.
  • Mutations in the Park-2 gene are a frequent cause of familial parkinsonism.
  • Parkin knockout (PK-KO) mice exhibit abnormalities similar to clinical PD.

Purpose of the Study:

  • To investigate the interaction of genetic and environmental factors in PD pathogenesis.
  • To examine the effects of rotenone (ROT) on neuronal cultures from PK-KO and wild-type (WT) mice.
  • To identify cellular mechanisms and potential therapeutic targets in PD models.

Main Methods:

  • Treatment of midbrain neuronal cultures from PK-KO and WT mice with rotenone (ROT).
  • Assessment of neuronal cell death (apoptosis, necrosis) and mitochondrial function.
  • Evaluation of the roles of microglia, inflammatory pathways (cyclo-oxygenase, nitric oxide synthase), and signaling pathways (MAPK).
  • Inhibition studies using caspase inhibitors, indomethacin, N-nitro-L-arginine methyl ester, minocycline, and MAPK inhibitors.
  • In vivo studies using PK-KO and WT mice treated with ROT.

Main Results:

  • ROT induced dose-dependent selective reduction of tyrosine hydroxylase-immunoreactive cells and other neurons in PK-KO cultures.
  • Neuronal death was primarily apoptotic and mediated by caspase activation.
  • PK-KO cultures showed increased susceptibility to ROT-induced apoptosis and glial activation.
  • Microglial NADPH oxidase inhibition and minocycline protected against ROT toxicity.
  • PK-KO mice were more susceptible to ROT toxicity than WT mice.

Conclusions:

  • Combined genetic deficiency (Park-2 suppression) and environmental toxin (ROT) exposure reproduce cellular events observed in Parkinson's disease.
  • Microglia play a critical role in mediating rotenone-induced dopaminergic neurodegeneration.
  • Minocycline, an inhibitor of microglia, demonstrated a protective effect, suggesting its potential therapeutic value in PD.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...